AzTrials
AzTrials

CataractNCT05323526

Validation of the Catquest-9SF Questionnaire in Greek Language

An observational study of Cataract and Catquest-9SF, run by Democritus University of Thrace at 2 sites in Greece.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Primary objective of this study is the validation of the Catquest-9SF questionnaire in the Greek population. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Cataract, Catquest-9SF
What is being tested?
Catquest-9SF questionnaire and Demographics and clinical parameters
How many people
100 participants
Where
2 sitesGreece
Study dates
15 Feb 2020to 15 Dec 2021
How long will I take part?
2 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients diagnosed with cataract who will undergo cataract surgery.

Who may be able to join

  • Patients with unilateral or bilateral senile cataract with stage 2 nuclear opalescence according to the Lens Opacities Classification System III (LOCS-3) grading scale, and no severe cognitive impairment during their preoperative examination.

Who cannot join

  • Patients with difficulty with the Greek language or dementia, Alzheimer's disease, severe stroke with mental disorder and conditions with the onset of mental retardation.

Trial locations and contacts

2 sites in 1 country.

Greece2 sites
  • Department of Ophthalmology, University Hospital of Alexandroupolis

    Alexandroupoli, Evros, 68100

  • General Hospital of Kalamata

    Kalamata, Messinia, 24100

Other trials in Greece

About this study

Primary objective of this study is the validation of the Catquest-9SF questionnaire in the Greek population.

Read the detailed description

The present study aims to validate the Catquest-9SF questionnaire in the Greek population. The Catquest-9SF is a questionnaire for assessing the quality of vision of patients with cataract. It consists of 9 questions, two of which concern the subjective assessment of the patient's vision and the other seven the patient's ability to perform various daily activities.

The Catquest-9SF questionnaire were translated into the Greek language by a translation team consisting of five members: one translation coordinator, two professional native English-speaking translators, one professional native Greek-speaking translator and one native Greek ophthalmologist fluent in English.

Patients participating in the study are asked to complete a questionnaire in Greek before and after cataract surgery. Upon completion of the data collection, data are processed and analyzed through Rasch analysis to determine whether the questionnaire can be used in clinical practice in this translated version.

The following clinical parameters are evaluated: age, gender, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.

Being tested
Catquest-9SF questionnaire, Demographics and clinical parameters
Keywords
cataract, catquest, validation, questionnaire, Rasch Analysis
Medical subject headings
Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Catquest-9SF questionnaireDiagnostic test

    Patients complete the questionnaire preoperatively and postoperatively.

  • Demographics and clinical parametersDiagnostic test

    The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.

Study groups in NCT05323526
Study groupRoleWhat they receive
Study Group100 patients who will undergo cataract surgery
Receives: Diagnostic Test: Catquest-9SF questionnaire; Diagnostic Test: Demographics and clinical parameters

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rasch Analysis: Response category ordering

    Response category ordering is evaluated graphically with category probability curves by observing whether the four response categories - omitting 'Cannot decide' as missing - (three category thresholds) are utilized in ascending order.

    Measured: 3 months

  2. Rasch Analysis: Item fit statistics [infit and outfit mean square (MNSQ)]

    Item fit statistics are used for the evaluation of the unidimensionality. When data fit well, the items should contribute to a single construct (visual disability) indicating the unidimensionality of the questionnaire (or the subscale). Both infit and outfit mean squares have an expected value of 1.0, with an ideal range of 0.7 to 1.3, and an acceptable range of 0.5 to 1.5) A value < 0.7 indicates too little variance and easily predicted questions, while > 1.3 indicates too much variance.

    Measured: 3 months

  3. Rasch Analysis: Principal components analysis (PCA)

    PCA is used for the evaluation of the unidimensionality. Two criteria are used; the PCA assessment is performed by comparing the amount of variance explained empirically and by the model, and the amount of variance explained by the first contrast (additional dimension). For unidimensionality, the unexplained variance in the first contrast of the residuals should be < 2.0 eigenvalue units, and ≥ 60% of variance should ideally be explained by the measure, while a percentage of ≥ 50% is acceptable.

    Measured: 3 months

  4. Rasch Analysis: Person Separation Index (PSI)

    PSI contributes to the assessment of the measurement precision of the Greek Catquest-9SF. PSI implies the questionnaire's ability to differentiate along its scale. The greater the value of person separation, the greater the questionnaire precision (acceptable person separation > 3.0).

    Measured: 3 months

  5. Rasch Analysis: Person Reliability (PR)

    PR contributes to the assessment of the measurement precision of the Greek Catquest-9SF. PR (ranging from 0 to 1) should be > 0.9 to be considered adequate, indicating a high ability to distinguish between the strata of person ability.

    Measured: 3 months

  6. Rasch Analysis: Differential Item Functioning (DIF)

    DIF indicates the differences between different subgroups of patients, since the questionnaire item calibration should be comparable across different patient groups. DIF occurs if patients from different subgroups with the same underlying true ability have an unequal probability of giving of a response to an item. DIF is assessed by evaluating age, gender, existence of ocular comorbidities, first vs second eye cataract surgery and binocular distance BSCVA. DIF of >1.0 logits is significant, DIF with values between 0.5 and 1.0 is minimal, and DIF <0.5 logits is considered absent.

    Measured: 3 months

  7. Rasch Analysis: Τargeting

    Τargeting of the questions to the patient sample, which indicates how well the items' difficulties match the person ability, is assessed to establish if the questions are appropriate for patients before and following cataract surgery. This can be assessed graphically by observing the spread along the person-item map and by the difference between the item and the person mean values. A well-targeted instrument requires the ability of the patients and the difficulty of the questions to be centered on the same mean (targeting of 0). In general, a mean difference in magnitude of ≥1 logit indicates significant mistargeting, while a difference of <1.0 logit indicates good targeting, with targeting of 0 being ideal. A positive value indicates that the items are too difficult relative to person's ability, while a negative value indicates that the items are too easy. A person-item map also visualizes the item hierarchy of difficulty, ranging from a minimum to maximum difficulty of performance.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2022
  2. Study start15 Feb 2020
  3. Primary completion15 Apr 2021
  4. Study completion15 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (actual)
Target duration
2 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT05323526
Sponsor's protocol ID
ES1/Th7/30-01-2020
Status last verified
Apr 2022
First submitted
5 Apr 2022
Last updated
19 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Nanos P, Kouteliari V, Panagiotopoulou EK, Papadopoulos N, Ntonti P, Labiris G. Catquest-9SF questionnaire: Validation in a Greek-speaking population using Rasch analysis. PLoS One. 2022 Dec 7;17(12):e0278683. doi: 10.1371/journal.pone.0278683. eCollection 2022.

    PubMed 36477289

Questions about this trial

What is this clinical trial studying?

An observational study of Cataract and Catquest-9SF, run by Democritus University of Thrace at 2 sites in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rasch Analysis: Response category ordering (time frame: 3 months). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05323526, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in